Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET
Status:
Withdrawn
Trial end date:
2021-02-20
Target enrollment:
Participant gender:
Summary
This study will formally address the hypothesis that FES-PET/CT measurement of ER expression
predicts clinical benefit of first-line endocrine therapy in newly diagnosed ER+ metastatic
breast cancer patients and establishes the repeatability of FES PET/CT.
Phase:
Phase 2
Details
Lead Sponsor:
Rathan Subramaniam University of Texas Southwestern Medical Center